Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 2Leukemia, Myeloid, Acute 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Burkitt Lymphoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 48Methotrexate 33Cytarabine 27fludarabine 23fludarabine phosphate 22Rituximab 22Filgrastim 21Vincristine 19Busulfan 19Whole-Body Irradiation 18Mycophenolic Acid 18Dexamethasone 18Antilymphocyte Serum 17Cyclosporine 16Etoposide 15Tacrolimus 14Melphalan 14Calcium Dobesilate 14pegaspargase 12Peripheral Blood Stem Cell Transplantation 12Doxorubicin 12Radiotherapy 11Clofarabine 11Granulocyte Colony-Stimulating Factor 10Thiotepa 9Bortezomib 9thymoglobulin 8Dasatinib 8Asparaginase 8plerixafor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Precursor Cell Lymphoblastic Leukemia-Lymphoma × tagraxofusp × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡